{"title":"《柳叶刀传染病》2025修订版;7月14日在网上发表。https://doi.org/10.1016/s1473 - 3099 (25) 00344 - 5","authors":"","doi":"10.1016/s1473-3099(25)00475-x","DOIUrl":null,"url":null,"abstract":"<em>Schnoz A, Sprecher VP, Biendl S, et al. Efficacy and safety of moxidectin–albendazole combination therapy for</em> Trichuris trichiura <em>infections in school-aged children: a double-blind, randomised, controlled, superiority trial.</em> Lancet Infect Dis <em>2025; published online July 14. https://doi.org/10.1016/S1473-3099(25)00344-5</em>—In this Article the labels for arithmetic mean eggs per g have been clarified in table 2. The sentence structure to paragraph five of the Results has been updated to remove ambiguity, but no results have been changed; the arithmetic mean reduction rate for moxidectin–albendazole has been corrected to 91·1%; and some appendix page numbers have been updated throughout the text. These corrections have been made to the online version as of July 25, 2025, and will be made to the printed version.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"2 1","pages":""},"PeriodicalIF":36.4000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Infect Dis 2025; published online July 14. https://doi.org/10.1016/S1473-3099(25)00344-5\",\"authors\":\"\",\"doi\":\"10.1016/s1473-3099(25)00475-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<em>Schnoz A, Sprecher VP, Biendl S, et al. Efficacy and safety of moxidectin–albendazole combination therapy for</em> Trichuris trichiura <em>infections in school-aged children: a double-blind, randomised, controlled, superiority trial.</em> Lancet Infect Dis <em>2025; published online July 14. https://doi.org/10.1016/S1473-3099(25)00344-5</em>—In this Article the labels for arithmetic mean eggs per g have been clarified in table 2. The sentence structure to paragraph five of the Results has been updated to remove ambiguity, but no results have been changed; the arithmetic mean reduction rate for moxidectin–albendazole has been corrected to 91·1%; and some appendix page numbers have been updated throughout the text. These corrections have been made to the online version as of July 25, 2025, and will be made to the printed version.\",\"PeriodicalId\":49923,\"journal\":{\"name\":\"Lancet Infectious Diseases\",\"volume\":\"2 1\",\"pages\":\"\"},\"PeriodicalIF\":36.4000,\"publicationDate\":\"2025-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s1473-3099(25)00475-x\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s1473-3099(25)00475-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
Schnoz A, Sprecher VP, Biendl S,等。莫西丁-阿苯达唑联合治疗学龄儿童毛癣菌感染的有效性和安全性:一项双盲、随机、对照、优势试验《柳叶刀传染病2025》;7月14日在网上发表。https://doi.org/10.1016/S1473-3099(25)00344-5在本文中,每克算术平均鸡蛋的标签已在表2中澄清。结果第5段的句子结构已经更新,以消除歧义,但结果没有改变;莫西丁-阿苯达唑的算术平均还原率修正为91·1%;一些附录页码已经在整个文本中更新了。截至2025年7月25日,这些更正已经对在线版本进行了修改,并将对印刷版本进行修改。
Correction to Lancet Infect Dis 2025; published online July 14. https://doi.org/10.1016/S1473-3099(25)00344-5
Schnoz A, Sprecher VP, Biendl S, et al. Efficacy and safety of moxidectin–albendazole combination therapy for Trichuris trichiura infections in school-aged children: a double-blind, randomised, controlled, superiority trial. Lancet Infect Dis 2025; published online July 14. https://doi.org/10.1016/S1473-3099(25)00344-5—In this Article the labels for arithmetic mean eggs per g have been clarified in table 2. The sentence structure to paragraph five of the Results has been updated to remove ambiguity, but no results have been changed; the arithmetic mean reduction rate for moxidectin–albendazole has been corrected to 91·1%; and some appendix page numbers have been updated throughout the text. These corrections have been made to the online version as of July 25, 2025, and will be made to the printed version.
期刊介绍:
The Lancet Infectious Diseases was launched in August, 2001, and is a lively monthly journal of original research, review, opinion, and news covering international issues relevant to clinical infectious diseases specialists worldwide.The infectious diseases journal aims to be a world-leading publication, featuring original research that advocates change or sheds light on clinical practices related to infectious diseases. The journal prioritizes articles with the potential to impact clinical practice or influence perspectives. Content covers a wide range of topics, including anti-infective therapy and immunization, bacterial, viral, fungal, and parasitic infections, emerging infectious diseases, HIV/AIDS, malaria, tuberculosis, mycobacterial infections, infection control, infectious diseases epidemiology, neglected tropical diseases, and travel medicine. Informative reviews on any subject linked to infectious diseases and human health are also welcomed.